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012.09.00Abstract Aim of the work: Assessment of synovitis in rheumatoid arthritis (RA) is a major issue
for proper treatment; it has been proven that high resolution ultrasound (US) examination could be
of valuable help. The B-cell chemokine, CXCL13, is a proposed serum biomarker of synovitis in
RA. We aimed to ﬁnd out the presence of synovitis in patients with recent-onset RA and its corre-
lation with disease activity.
Patients and methods: We evaluated 30 patients with early RA for the presence and degree of
synovitis by performing high resolution US and obtaining serum CXCL13 levels. In addition, we
correlated these results with disease activity score 28 (DAS 28). Results of high resolution US
and serum CXCL13 were also obtained for 20 healthy age- and sex-matched volunteers and served
as controls.
Results: Serum CXCL13 level was signiﬁcantly increased in early RA patients vs. controls
(p< 0.001). High resolution US revealed that RA patients had a signiﬁcant increased synovial
thickness and high power Doppler US score. In RA patients, DAS 28 had a signiﬁcant correlation
with serum CXCL13 (r= 0.42, p= 0.02), synovial thickness (r= 0.39, p= 0.03) and power
Doppler US score (r= 0.43, p= 0.02). Serum CXCL13 level correlated with synovial thickness
(r= 0.63, p= 0.001) and power Doppler US score (r= 0.69, p= 0.001).com (S. Fathi Ahmed).
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22 S. Fathi Ahmed et al.Conclusion: Recent-onset RA patients suffer from synovitis as evidenced by signiﬁcantly
increased serum CXCL13 and by high resolution US. Serum CXCL13 is a reliable marker of syno-
vial inﬂammation which correlates better with synovial thickening and power Doppler US scores
than DAS28.
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Rheumatoid arthritis (RA) is a chronic autoimmune disease
targeting multiple joints. The synovium is the primary site of
the inﬂammatory process, which if untreated leads to irrevers-
ible damage to the adjacent cartilage and bone [1]. This process
is characterized by an increased presence of monocytes, macro-
phages, and lymphocytes in the synovial ﬂuid and tissue, lead-
ing to the release of cytokines and chemokines. These
proinﬂammatory mediators subsequently activate different
proteases, culminating in the destruction of bone and cartilage,
which leads to increased disability in RA patients [2].
Serum levels of the B-cell attracting chemokine, CXCL13
have been proposed as a marker of synovitis in rheumatoid
arthritis [3,4]. CXCL13 and its receptor CXCR5 serve a
homeostatic role in the immune system. CXCL13 is constitu-
tively expressed in the B-cell areas of secondary lymphoid tis-
sues such as spleen and lymph nodes [5]. CXCL13 directs
circulating B cells and follicular T-helper cells to home to the
B-cell area during lymphoid organ development and routine
immune surveillance [6].
In addition, CXCL13 and CXCR5 also participate in the
pathogenesis of certain chronic inﬂammatory diseases. Under
these conditions, CXCL13 expression is induced at nonlym-
phoid inﬂammatory sites and participates in ectopic germinal
center formation. These ectopic germinal centers provide an
optimal microenvironment for B-cell activation, differentia-
tion, maturation, and autoantibody generation, resulting in
accelerated disease progression [7].
Rheumatoid arthritis (RA) is characterized by synovial
inﬂammation and bone and cartilage destruction. While syno-
vial inﬂammation is typically assessed by physical examina-
tion, measurement of bone and cartilage damage is a domain
of radiography. In recent years, high-resolution ultrasound
(US) has been increasingly used to assess synovial inﬂamma-
tion [8]. With US, one can quantitatively assess the morpho-
logic (synovial thickness) and functional (blood ﬂow)
changes of joints during inﬂammatory arthritis [9].
Clinical trials concerning RA are based upon various com-
posite indices for assessing disease activity like disease activity
score 28 (DAS28), health assessment questionnaire (HAQ),
clinical disease activity index (CDAI) and the simpliﬁed dis-
ease activity index (SDAI). They have proven sensitivity to
change, validity and reliability; unfortunately they are mainly
based on subjective issues like patient’s appreciation of pain,
while, US was proven to be better than clinical examination
in detecting synovitis [10].
Therefore, we aimed to assess the presence and severity of
synovitis in patients with early rheumatoid arthritis by high
resolution power Doppler ultrasonography and by measuring
serum CXCL13 and to correlate these ﬁndings with the clinical
disease activity.2. Patients and methods
Thirty patients with early RA (disease duration less than
1 year) were selected from those presenting to the Internal
Medicine and Physical Medicine, Rheumatology, and Rehabil-
itation outpatient clinics of the Ain Shams University Hospi-
tals. RA patients were all fulﬁlling the new EULAR/ACR
criteria for RA. A score of P6/10 is needed for classiﬁcation
of a patient as having deﬁnite RA [11]. All patients had clinical
arthritis during examination. They were on methotrexate, folic
acids and hydroxychloroquine, in addition to corticosteroids
during ﬂaring up of the disease.
The control group consisted of 20 healthy, age- and gender-
matched volunteers. The study protocol was in accordance
with Helsinki declaration of human rights, and was approved
by the local Ethics Committee. The written informed consent
from each patient and control was obtained.
All patients were subjected to the following:
1. Full history taking and thorough physical examination
including detailed musculoskeletal examination.
2. Assessment of disease activity by using the modiﬁed DAS-
28 score. A patient with DAS-28 score 62.6 is considered in
remission, from 2.6 to63.2 = low disease activity, from 3.2
to <5.1 = moderate disease activity and >5.1 = high dis-
ease activity [12].
3. Functional assessment was done by using the health assess-
ment questionnaire (HAQ) score (validated Arabic version)
[13].
4. Radiological examination:
– Plain X-ray of hands was done on all RA patients and
X-ray score was calculated according to Larsen et al.
[14].
– High resolution US using a gray-scale US mode (13–1-
8 MHz), Philips HD 11, by an expert radiologist was
done on all patients and controls. The patient was seated
with hands lying in prone position on the examination
table. Both longitudinal and transverse scans were per-
formed by slightly moving the transducer from radial to
ulnar and from proximal to distal sides on the dorsal
aspect to enable maximum coverage of the anatomical
surface areas. The sites that were assessed by US included
the dorsal regions of the 2nd MCP joint, 3rd MCP joint,
and the dorsal regions of the wrist [15].The intraarticular,
tenosynovial and intrabursal powerDoppler (PD) signals
were graded on a semi-quantitative scale from 0 to 3 (g-
rade 0 = absence, no synovial ﬂow; grade 1 = mild, <3
isolated signals; grade 2 = moderate, >3 isolated signals
or conﬂuent signals in less than half of the synovial area;
grade 3 = marked, signals in more than half of the syn-
ovial area). These scores corresponded to the maximum
score for PD signals obtained from any of the synovial
Table 1 Clinical data of RA patients.
Clinical data RA patients (n= 30)
Min.–Max. Median Mean ± SD
DAS 28 3.35–7.32 5.7 5.44 ± 0.92
HAQ 1–3 3 2.65 ± 0.58
Score of diagnosis 6–8 7 7.1 ± 0.75
Assessment of synovitis in early rheumatoid arthritis by CXCL13 serum levels 23sites evaluated at each joint. The sum of the PD signal
scores obtained from each joint was used as the PDUS
score, as reported by Naredo et al. [10].For better asses-
sment of synovitis by US, the number of scanned joints
should range from 6 to 12 joints [16]. For better clinical
availability, Kawashiri et al. [15] and Taylor et al. [17]
reduced the number of joints examined by US to only six
sites of the wrist and ﬁnger joints. Since the second and
the third metacarpophalangeal (MCP) joints showed the
most radiological ﬁndings as regarded by Naredo et al.
[10], we have chosen six synovial sites from six joints in-
cluding the bilateral wrists (dorsal recess) and second and
third MCP joints (dorsal recess). The six joint (6j)-PDUS
score was the sum of the six synovial sites.
5. Laboratory investigations
– Complete blood count (CBC), Erythrocyte sedimenta-
tion rate (ESR) in ﬁrst hour in mm/hr.
– Serum anti CCP antibodies level was assessed by ELISA
using QUANAT Lite CCP3 IgG semiquantitative
ELISA kit, INOVA Diagnostics, Inc., San Diego, CA,
USA. Serum samples of anti CCP antibody levels less
than 20 U/ml were considered negative, and designated
as the ‘‘standard’’ cut off.
– Rheumatoid factor (IgM) was measured by Biotec, that
was the factor latex agglutination slide for qualitative
determination of RF in serum.
– Serum CXCL13 level was quantitatively determined
using Human CXCL13 enzyme linked immunosorbent
assay (ELISA) (RayBio, RayBiotech, Inc., USA) [18].
Statistical methods: IBM SPSS statistical software package
(V. 19.0, IBM Corp., USA, 2010) was used for data analysis.
Data were expressed as range (minimum–maximum),
mean ± SD and median for quantitative measures and both
number and percentage for categorical data. Comparison be-
tween two independent groups of numerical parametric data
was done using Student’s t-test. Ranked Spearman correlation
test was done to study the possible association between each of
the two variables among each group for nonparametric data.
Probability of error at <0.05 was considered signiﬁcant and
highly signiﬁcant at <0.001.3. Results
This study included 30 patients with early rheumatoid arthritis
(27 females and 3 males). Twenty healthy subjects (18 females
and 2 males) served as the control group. The patients’ age
ranged from 24 to 60 years, with a mean of 37.5 ± 10.4 years,
this was matched with the age of the control group that ranged
from 25 to 59 years, with a mean of 37.8 ± 10.1 years. The dis-
ease duration ranged from 6 to 12 months; with a mean of
9.2 ± 2.7 months.
The score of diagnosis in early RA patients ranged from 6
to 8. So, all these patients were diagnosed as deﬁnite RA
according to the new EULAR/ACR diagnostic criteria for
RA. Disease activity score (DAS 28) ranged from 3.35 to
7.32 with a mean of 5.44 ± 0.92. Health assessment question-
naire score (HAQ) ranged from 1 to 3 with a mean of2.7 ± 0.5 (Table 1). Plain X-ray score (Larsen score) ranged
from 0 to 2 with a mean of 1.5 ± 0.7.
High resolution US revealed highly signiﬁcant increased
synovial thickness (p< 0.001) in the examined 6 joints that
ranged from 0.7 to 4.1 mm with a mean of 1.8 ± 0.95 mm in
comparison to the control group that ranged from 0.3 to
0.5 mm with a mean of 0.4 ± 0.08 mm.
Power Doppler US score measured in each joint was grade
1 or 2 in all patients (no marked grade; grade 3 in any exam-
ined joint). So, power Doppler US score measured in all 6
joints of RA patients ranged from 6 to 12 with a mean of
8.37 ± 2.15. On the other hand, power Doppler US score in
the control group was 0 in all 6 joints.
ESR levels ranged from 20 to 120 mm/h in RA patients
with a mean of 45.47 ± 26.25 mm/h. Rheumatoid factor was
positive in 26 RA patients (86.7%).While, serum anti CCP
antibodies was positive in 25 RA patients (83.3%).
Serum CXCL13 levels ranged from 120 to 350 pg/ml in RA
patients. When compared with a range of 8–30 pg/ml in the
control group, there was a highly signiﬁcant elevation in serum
CXCL13 levels in RA patients versus controls (p< 0.001),
(Table 2 and Fig. 1).
In RA patients, DAS 28 score showed signiﬁcant correla-
tion with serum CXCL13 levels (r= 0.42, p= 0.02) and also
with synovial thickness (r= 0.39, p= 0.03) and power Dopp-
ler US score (r= 0.43, p= 0.02).
On the other hand, the serum levels of CXCL13 in RA pa-
tients correlated with the synovial thickness (r= 0.63,
p= 0.001) (Fig. 2) and with PDUS score (r= 0.69,
p= 0.001) (Fig. 3), while there was an insigniﬁcant correlation
between serum CXCL13 levels and either ESR, HAQ or Lar-
sen score (p> 0.05) Figs. 4–6 show ultrasonographic ﬁndings
in RA patients and controls.
4. Discussion
Serum levels of the B-cell attracting chemokine, CXCL13 have
been proposed as a marker of synovitis, and predicted synovi-
tis outcomes in patients with recent-onset RA [4,18]. In this
study, we aimed to ﬁnd out the presence and severity of syno-
vitis in early rheumatoid arthritis patients by high resolution
power Doppler US and by measuring serum CXCL13 and cor-
relate these ﬁndings with the disease activity.
There may be many sources of serum CXCL13, including
lymph nodes [19]. Manzo et al. [20] reported that serum
CXCL13 levels can be changed in association with active
RA. So, synovitis appears to signiﬁcantly contribute to the sys-
temic up-regulation of CXCL13 [3]. Furthermore, during
inﬂammation, the released interleukins induce the production
of acute phase proteins from hepatocytes [21]. The assessment
of CXCL13 levels in the peripheral circulation may be used as
Figure 1 Comparison between RA patients and controls as regards serum CXCL13 levels.
0.5
1
1.5
2
2.5
3
3.5
4
4.5
110 160 210 260 310
CXCL 13 (pg/ml)
 
Sy
n
o
vi
al
 th
ic
kn
es
s 
(m
m)
     r = 0.63, p = 0.001 
    X axis represents CXCL 13, Y axis represents synovial thickness. 
Figure 2 Correlation between serum CXCL13 levels and syno-
vial thickening as measured by high resolution US in RA patients.
5
6
7
8
9
10
11
12
13
14
15
110 160 210 260 310
CXCL 13 (pg/ml)
Po
w
er
 
 
D
op
pl
er
 s
co
re
 
     r = 0.69, p = 0.001
    X axis represents CXCL 13, Y axis represents power Doppler score.
Figure 3 Correlation between serum CXCL13 levels and PDUS
score in RA patients.
Table 2 Comparison between RA patients and controls as regards serum CXCL13 levels.
RA patients (n= 30) Controls (n= 20) P
Min.–Max. Median Mean ± SD Min.–Max. Median Mean ± SD
CXCL13 (pg/ml) 120–350 145 165.4 ± 49.4 8–30 15 15.7 + 5.9 0.001
24 S. Fathi Ahmed et al.a comprehensive, non-invasive tool to gain further information
on the clinical signiﬁcance of synovitis in RA [22].
Our results showed that serum levels of CXCL13 were sig-
niﬁcantly higher in RA compared to healthy controls. This was
in agreement with Bugatti et al. [18] and Manzo et al. [23],whose studies were also on early RA (disease duration less
than 12 months).
In the present study, we used three scoring systems; clinical
score (DAS 28), functional score (HAQ) and radiological scor-
ing system to assess the disease activity, the related disability
and the extent of synovitis respectively in early RA patients.
Figure 4 Longitudinal scan of the dorsal aspect of the right second MCP joint of RA patient showing moderate arthro-synovial
proliferation (arrowed) in (a) with mild vascularity shown in (b), grade 1. The normal sonographic appearance of the MCP joint from the
healthy control is demonstrated for comparison in (c), the arrow head points to the head of metacarpal and the star to the base of
proximal phalanx.
Figure 5 Transverse scan of the dorsal aspect of the right wrist joint of RA patient showing moderate arthro-synovial proliferation with
bony erosions (black arrow) in (a) with moderate vascularity shown in (b), grade 2. X ray wrist of the same RA patient in (c) showing
evident erosions (white arrow) with lost joint spaces between carpal bones. For comparison normal sonographic wrist joint is shown in (d)
with a smooth outline of carpal bones and normal thin synovium.
Assessment of synovitis in early rheumatoid arthritis by CXCL13 serum levels 25DAS 28 was signiﬁcantly correlated with serum CXCL13
levels and also with measures of synovitis; synovial thickness
and power Doppler US score. Other studies showed signiﬁcant
association between serum CXCL13 levels and either objective
or semi-objective measures of disease activity, such as the
swollen joint count, the evaluator global assessment of disease
activity, the erythrocyte sedimentation rate and C-reactive pro-
tein levels [23,24]. Also Kawashiri et al. [15] revealed that
DAS-28 was of better correlation with the PDUS score than
SDAI and CDAI, and these data reinforce the validity of
PDUS for the measurement of the disease activity of RA.As regards the functional score, there was insigniﬁcant
correlation between HAQ and either serum CXCL13 levels
or measures of synovitis. This may be explained by two
reasons; ﬁrst: the short disease duration of our patients (less
than one year) and the second is that not one of our patients
had severe synovitis (grade 3 by power Doppler US).
It is widely accepted now that US is more accurate than
clinical examination in detecting synovitis [10], and PD tech-
nologies further improve the capability of identifying actively
inﬂamed joints [25]. We agree with Backhaus et al. [26] that
power Doppler US is a noninvasive, relatively inexpensive bed-
Figure 6 Transverse scan of the dorsal aspect of the right wrist joint of RA patient showing moderate arthro-synovial proliferation
(black arrow) in (a) with moderate tenosynovitis of the extensor carpi ulnaris tendon (white arrow) shown in (b), with mild vascularity,
grade 1 as shown in (c).
26 S. Fathi Ahmed et al.side imaging modality that facilitates the scanning of all
peripheral joints as many times as required.
We found that serum levels of CXCL13 correlated with the
severity of synovitis as assessed by US (synovial thickness and
PDUS score). Thus, measurement of CXCL13 levels may help
to predict active joint inﬂammation that was detected by
power Doppler US and help in the assessment of the degree
of synovitis compared to other routine markers (acute phase
proteins as ESR and C reactive proteins) that are only indi-
rectly linked to joint inﬂammation. Also, Bugatti et al. in
2012 [18] found that serum CXCL13 was signiﬁcantly corre-
lated with the baseline PD scores and serum CXCL13 levels
emerged as the only baseline predictor of US outcomes in their
cohort in comparison to CRP or ESR serum levels.
There was no signiﬁcant correlation between serum
CXCL13 levels and the Larsen score in our cohort. On the
other hand, Meeuwisse’s et al. [27], showed that higher
CXCL13 serum levels were reported to be associated with in-
creased rates of joint destruction in their long term study.
In conclusion, synovial hypertrophy in early RA patients
can be detected by high resolution power Doppler US. The
use of power Doppler US in assessing early synovial hypertro-
phy is a non invasive, easily used and reproducible tool for the
evaluation of the severity of synovitis in these patients. Serum
CXCL13 can be used as an early new biological marker that
gives an idea about the severity of synovitis and activity of
the disease. Serum CXCL13 levels correlated better with syno-
vial thickening and power Doppler score than DAS 28. So,
screening of early RA patients for synovitis is recommended
by either measuring serum CXCL13 or by high resolution
US for better assessment and management of the disease.Conﬂict of interest
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